<DOC>
	<DOCNO>NCT00714623</DOCNO>
	<brief_summary>This study prospective , non-randomized , open-label registry consecutive patient CAD treat stent-assisted PCI use least one CypherTM stent . Up 1000 pt include registry . The registry conduct evaluation impact CypherTM Sirolimus-eluting stent implantation `` real world '' interventional cardiology . Informed consent obtain patient meet inclusion criterion initiation study specific procedure . Consecutive patient treat use CypherTM stent include registry . Baseline post-procedure blood sample use perform platelet function analysis use Accumetrics Ultegra RPFA ( Rapid Platelet Function Assay ) . All patient follow enrollment hospital discharge clinically significant event ( death , myocardial infarction , TLR , TVR , major minor bleeding ) . A follow-up telephone assessment death , myocardial infarction , revascularization , medical treatment conduct experience research personnel 30 day , 6 month , 1 year least 2 year . All site report death , myocardial infarction revascularizations adjudicate independent Clinical Events Committee 1000 patient enrol trial . An interim analysis first 750 patient conduct data forward FDA .</brief_summary>
	<brief_title>The SCRIPPS DES REAL WORLD Registry</brief_title>
	<detailed_description />
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Coronary Restenosis</mesh_term>
	<mesh_term>Coronary Thrombosis</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>1 . Age 18 year old 2 . Eligible percutaneous coronary intervention 3 . Patient least one lesion â‰¥50 % diameter stenosis require PCI stenting 4 . Reference vessel diameter 2.254.0 mm 5 . Percutaneous intervention use one FDA approve CypherTM stent , plan exceed 108 mm stent length . 6 . Target lesion locate within native coronary artery bypass graft 7 . De novo restenotic lesion , include ISR , radiation failure 8 . Be reliable , cooperative willing comply protocolspecified procedure followup 9 . Able understand grant inform consent 1 . Confirmed pregnancy time index PCI 2 . Has know allergy aspirin , clopidogrel ( PlavixTM ) ticlopidine ( TiclidTM ) 3 . Has know allergy contraindication heparin Bivalirudin ( AngiomaxTM ) 4 . Known allergy sensitivity component Sirolimuseluting stent 5 . Has significant medical condition investigator 's opinion may interfere patient 's optimal participation study ; 6 . Any serious disease condition life expectancy le 1 year .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Coronary Artery Disease</keyword>
	<keyword>Coronary Restenosis</keyword>
	<keyword>Coronary Thrombosis</keyword>
	<keyword>Drug-Eluting Stents</keyword>
	<keyword>Angioplasty , Transluminal , Percutaneous Coronary</keyword>
</DOC>